Rybelsus, the original oral semaglutide product approved back in 2019, picked up a meaningful new indication in October 2025: the FDA approved a supplemental new drug application covering the 7 mg and 14 mg doses to reduce the risk of major adverse cardiovascular events (MACE) — heart attack, stroke, and cardiovascular death — in adults with type 2 diabetes. It’s a quieter approval than a brand-new drug launch, but it matters, because it extends cardiovascular protection to a pill that millions of diabetes patients are already taking, rather than requiring a switch to an injectable.
What Changed
Rybelsus has been approved for glycemic control in type 2 diabetes since 2019, but its label didn’t previously include a cardiovascular risk reduction claim — that distinction had largely belonged to injectable semaglutide (Ozempic), which picked up its own MACE reduction indication years earlier based on the SUSTAIN-6 and SELECT trial programs. The October 2025 approval closes that gap for the oral formulation, meaning patients and prescribers no longer have to choose between the convenience of a pill and a documented cardiovascular benefit — both are now available in the same tablet.
Why This Matters for Patients
Cardiovascular disease remains the leading cause of death for people with type 2 diabetes, and GLP-1 drugs have increasingly been shown to reduce that risk independent of their glucose- and weight-lowering effects. For patients already managing diabetes with Rybelsus who were previously told an injectable would be needed to get cardiovascular protection, this approval removes that trade-off. It’s also a reminder that the GLP-1 story in 2025 wasn’t only about new molecules and headline weight-loss numbers — a meaningful share of the year’s real progress came from expanding what already-approved drugs are proven to do.
Frequently Asked Questions
Is this a new drug?
No. Rybelsus (oral semaglutide) has been on the market since 2019. This approval adds a cardiovascular risk reduction indication to its existing 7 mg and 14 mg doses, based on new trial data submitted to the FDA.
How is this different from the Wegovy pill?
Rybelsus and the Wegovy pill are both oral semaglutide products using the same absorption-enhancer technology, but they’re approved for different primary uses and doses — Rybelsus for type 2 diabetes management (now with cardiovascular risk reduction), and the Wegovy pill specifically for weight management and its own cardiovascular indication.
Does this apply to people without diabetes?
No. This specific approval covers cardiovascular risk reduction in adults with type 2 diabetes. Cardiovascular risk reduction in people without diabetes falls under separate approvals for other semaglutide products.
This article is for educational purposes only and summarizes publicly available FDA information. It is not medical advice.